India didn't violate multilateral trade agreements by granting a compulsory license for Bayer's cancer treatment Nexavar in order to make it cheaper, Indian Commerce and Industry Minister Anand Sharma told U.S. Economic Growth, Energy and Environment Undersecretary Robert Hormats. An official said that Hormats raised the issue and said patent holders need to know the action will not become routine.

Full Story:
The Hindu (India)

Related Summaries